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improvement from baseline to week 26, in 7 of 8 SF-36 domains, versus non-re-
sponders, and 2 to 8 times greater improvement in HAQ. Patients attaining low
disease activity (Sub-group C) experienced the greatest differences. For Sub-group
B, where cohorts had the most comparable baseline scores, results were statisti-
cally significant for HAQ (p0.0012) and 6 of 8 SF-36 domains (p0.01 except role-
emotional and mental health domains). CONCLUSIONS: Patients able to attain
T2T-related response achieved significantly greater absolute improvement in
health status versus non-responders, in HAQ and 6 of 8 SF-36 domains. There may
be additional value in adding change scores to threshold values in current T2T
objectives for severe patients and consideration of patient functionality may be
warranted.
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ARTHRITIS
Bolge S1, Schenkel B1, Ramesh V2, Ingham M1
1Janssen Scientific Affairs, LLC, Horsham, PA, USA, 2Kantar Health, New York, NY, USA
OBJECTIVES: To describe the shared decision-making process between patients
and physicians when initiating biologic therapy for the treatment of rheumatoid
arthritis (RA) from the patient perspective. METHODS: Patients self-reporting a
diagnosis of RA completed a self-administered, internet-based questionnaire in
the Fall of 2011. A subset of patients currently using a biologic therapy to treat their
RA provided details about the decision-making process for initiating their current
therapy. RESULTS: A total of 2138 respondents (76% female, mean age 56.4) com-
pleted the questionnaire. Of these, 20% (n434) were currently being treated with
biologic therapy. Discussions about biologic therapy weremost often initiated by a
rheumatologist (91%); only a small proportion of patients reported that a primary
care physician (4%), the patient themselves (3%), or another (2%) initiated the dis-
cussion. During the discussions, physicians most often focused on administration
(77%), dosing schedule (77%), side effects (71%), safety risks (64%), importance of
long-term use (57%), and importance of concomitant methotrexate use (53%). Pa-
tients rated the following as very or extremely influential (4 or 5 on a 5-point Likert
scale) on the final decision to initiate biologic therapy: advice or recommendation
by physician (76%), co-pay assistance to cover out-of-pocket costs (31%), advice or
recommendation from other healthcare professional (28%), patient literature ma-
terials from physician office (27%), and information from general websites (22%).
Most patients (71%) reported making the decision to start biologic therapy at the
time of the initial discussion with their physician; mean time for all patients to
make a decision to start biologic therapy was 12.2 days from the time of initial
discussion. CONCLUSIONS: Rheumatologists are best positioned to ensure that
patients have the necessary information to actively engage in the shared decision-
making process for initiating biologic therapy. Future research should focus on
potential outcomes benefits of shared decision-making.
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DISEASE ACTIVITY SCORE AND PROVISIONAL CRITERIA BY AMERICAN
COLLEGE OF RHEUMATOLOGY AND EUROPEAN LEAGUE AGAISNT
RHEUMATISM: ANALYSIS BASED ON PATIENT REPORTED OUTCOMES FROM 3
PHASE III CLINICAL TRIALS OF GOLIMUMAB
Han C1, Keystone E2, Fleischmann R3, Smolen JS4, Emery P5, Genovese M6, Doyle M7,
Hsia E7
1Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, USA, 2Mount Sinai Hospital,
Toronto, ON, Canada, 3University of Texas, Dallas, TX, USA, 4Medical University of Vienna and
Hietzing Hospital, Vienna, Austria, 5University of Leeds, Leeds, UK, 6Stanford University, Palo
Alto, CA, USA, 7Janssen Research & Development, LLC, Spring House, PA, USA
OBJECTIVES: Remission by Boolean-based definition(all scores on the TJC and SJC-
,CRP(mg/dl), and PGA1) and by SDAI(3.3) were proposed by ACR/EULAR.Using
patient reported outcomes as anchors, this analysis validated these remission cri-
teria against traditional DAS28(using CRp2.6)remission. METHODS: Efficacy of
golimumab(GLM) was assessed in MTX-naïve RA patients(GO-BEFORE, N637),
RA patients with inadequate response to MTX (GO-FORWARD,N444) and RA
patients previously treated with biologic anti-TNF agent(s) with baseline MTX
use(GO-AFTER,N305).Pooled data from patients who received placebo
(PBO)MTX, or GLM(50or100mg)MTX,q4wks were used for this analysis.Pa-
tient reported outcomes were measured using:HAQ, SF-36 PCS and MCS, FACIT-
Fatigue, and VAS 0-10 of impact of RA on daily work productivity.Descriptive
statistics were provided for patient reported outcomes among patients in re-
mission as defined remission definitions. RESULTS: Greater proportions of pa-
tients treated with GLMMTX vs patients treated with PBOMTX achieved remis-
sion by each remission definition.In the pooled analysis,the remission rate at wk24
was the highest(20.2%)by DAS28 vs remission by SDAI(10.6%, p0.001) and remis-
sion by Boolean-based definition(8.6%p0.001).Patients with remission by DAS28
achieved normal physical function(HAQ0.5),normal SF-36PCS and MCS(50) by
67.8%,38.4%,62.2%,respectively;these parameters were numerically lower vs. pa-
tientswith remission by SDAI(81.3%,62.8%,72.1%,respectively) or by Boolean-based
definition(82.0%,63.5%,74.3%, respectively). Patients in remission by DAS28 had
higher HAQ scores(0.430.49)vs patients in remission by SDAI(0.260.41) or Bool-
ean-based criteria(0.280.44).Similar results were observed in measures of FACIT-
Fatigue and productivity VAS scores.Among MTX-naive patients in GO-BEFORE
who achieved remission by DAS28,71.3% achieved normal physical function vs
86.9% of those in remission by SDAI and 86.5% of patients in remission by Boolean-
based definition.Among anti-TNF experienced patients in GO-AFTER,62.1% of
those in remission by DAS28 achieved normal physical function vs. 65.0% of those
in remission by SDAI, and 66.7% of patients in remission by Boolean-based
definition.CONCLUSIONS:While disease remission has been adapted as a target in
the management of RA, more stringent remission criteria proposed by ACR/EULAR
can provide optimal patient-reported outcomes.
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OBJECTIVES: To examine the relationship of health care costs with baseline demo-
graphic and clinical characteristics for rheumatoid arthritis (RA) patients.
METHODS: Adult RA patients (ICD-9: 714.XX) treated with anti-tumor necrosis
factors (anti-TNFs) were identified from a large US commercial claims database
(June 2004-June 2009). Patientswho switched to another anti-TNF or escalated their
dosage were identified between the initial anti-TNF date and June 2008. Total and
RA-related health care costs were calculated during the 12-month period after
switch or dose escalation. Scatter plots and box plots were drawn to examine the
relationship between age, gender, comorbidity indexes, baseline costs and total
all-cause and RA-related health care costs. RESULTS: A total of 2587 RA patients
with a mean age of 55.9 were included in the final sample. 23.5% of these patients
were insured by Medicare and 76.5% by commercial health plans. Scatter plots
illustrate a slightly positive relationship between age and total health care costs in
the commercial population. Moreover, a stronger positive trend exists between the
Charleston Comorbidity Index (CCI) and total health care costs but not with RA-
related health care costs in the commercial population. Chronic Disease Score
(CDS) shows the same trend as CCI. A positive relationship can also be seen be-
tween baseline health care costs and follow up all-cause or RA-related costs. The
majority of observationswere clustered at the lower end of the domain.We further
examined the relationships in the patient populations treated with and without
methotrexate, and the results were similar. CONCLUSIONS: There were strong
positive relationships between baseline and follow-up health care costs among RA
patients who initiated anti-TNFs and subsequently switched to another drug or
escalated their dosage. The positive relationships between CCI and CDSweremore
prominent in the commercially-insured patient population.
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OBJECTIVES: To develop and test an ePRO system for routine collection of surgical
outcomes in a busy orthopaedic clinic. METHODS: We developed an ePRO (iPad)
version of the widely adopted Oxford Knee (OKS) and Shoulder (OSS) scores. A
multi-stage process was undertaken to ensure ePRO versus paper version equiva-
lence involving the PRO instrument developer, PROmanager, PRO translation spe-
cialists as well as surgeons and Electronic Management Record (EMR) hospital
specialists. This included, a review of the draft ePRO version; pilot-testing (cogni-
tive debriefing and usability testing) on five patients attending an outpatients clin-
ic; with pilot-tested results reviewed to ensure no issues arose during migration to
ePRO. RESULTS: The ePRO version of both questionnaires were shown, from pilot-
testing, to be easy to use. Compared with OKS and OSS paper versions, ePRO re-
sponses were all legible (an issue for some Rheumatoid patients) and complete.
ePRO completion also takes care of data entry, resulting in a dataset free of errors
that might otherwise arise. This suggested the potential for higher return rates
with reducedhandling costs. Following reviewof pilot-testing, no significant issues
were identified, so the final ePRO versionswere adopted. Secure synchronisation of
the completed ePRO results with the local EMR system proved straight-forward,
required little data cleaning and provided almost immediate feedback of outcomes
to clinicians. CONCLUSIONS: Initial results demonstrated the OKS and OSS have
been successfully migrated to the ePRO (iPad) version, with results from pilot-
testing demonstrating that the validity of the original PRO instrument is retained.
ePRO completion enters scores instantaneously on the local EMR system and as a
result routine collection of a high volume of PROs could be achieved efficiently.
This development facilitates the collection of PRO measure data within the clinic
setting, highlighting their potential to enhance patient-centred care across the
patients care pathway.
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OBJECTIVES: To compare the health-related quality of life of patients with self-
reported Rheumatoid Arthritis to statistically matched patients without Rheuma-
toid Arthritis. METHODS: The study utilized a cross-sectional population-based
design, in which respondents, representing non- institutionalized adults in the
United States of ages 18 or above, were chosen from the 2006 Medical Expenditure
Panel Survey (MEPS). Respondents were included in the self-reported Rheumatoid
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Arthritis (RA) group with a clinical classification category of CCC 202. They were
matched with an equal number of respondents without RA as controls in order to
minimize the sample selection bias, using Greedy Match Propensity Score Match-
ing. Pre-disposing, enabling and need variables were matched using Chi-square
tests for categorical variables and t-tests for continuous variables in SAS, version 9.
Health-related quality of life instruments usedwere the Physical Component Sum-
mary (PCS-12) and the Mental Component Summary (MCS-12) of the SF-12 Health
Survey and the EuroQol 5D index. T-tests in STATA (R) were used to measures
group differences. RESULTS: Patients were statiscally matched on nine of ten vari-
ables. Themean (SE) PCS-12 scores for the RA and Non-RA groups were 34.25 (1.03)
and 45.46 (1.07). The mean (SE) MCS-12 scores for the RA and Non-RA groups were
47.50 (1.01) and 51.14 (0.83). The mean (SE) EQ-5D index scores for the RA and
Non-RA groups were 0.74 (0.02) and 0.86 (0.01). All lower scores were significant at
an a priori alpha value of 0.05. CONCLUSIONS: Lower scores on all measures indi-
cate that non- institutionalized adultswith self-reported RheumatoidArthritis (RA)
have a significantly lower health-realated quality of life.
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Fibromyalgia syndrome (FMS) is amulti-symptomdisorder primarily characterizedby
pain. In addition to pain, other symptoms include fatigue, irritable bowel disorder,
psychological disturbances like anxiety, depression, cognitive dysfunction etc. The
ambiguity of the symptoms and their overlapping naturewith other rheumatic disor-
ders poses a huge problem in diagnosis. Meanwhile, patient’s quality of life (QoL) is
compromised and deteriorates further. Hence, a thorough exploration in a clinical
setting is necessary. Generic instruments lack specificity,while the burgeoning symp-
tomspecific instruments present great respondent burden. Validated disease-specific
instruments seem to offer the best medium for complete evaluation of FMS patients.
OBJECTIVES: To identify available validated disease-specific instruments to enable
a comprehensive evaluation of fibromyalgia patients in a clinical setting.The ojec-
tive of this review is to provide clinicians and researchers with summarized infor-
mation on the available instruments and aid them in diagnosis of this disorder.
METHODS: A comprehensive literature review from January 1990 to June 2011 was
conducted with the combination of following key words fibromyalgia, disease-
specific, questionnaires, instruments etc. 58 articles that dealt with disease-spe-
cific instruments in FMS were identified of which 9 articles were included in the
final review. RESULTS: Only nine disease-specific instruments were identified in
literature which can be classified as: a) Diagnostic tools (2 instruments); b) QoL
evaluation tools (6 instruments); and c) Disease knowledge assessment tools (1
instrument). Most instruments possess strong psychometric properties that have
been tested in fibromyalgia patients. This review describes the instruments with
respect to their psychometric properties, strengths, and limitations.
CONCLUSIONS:These instruments can serve as supplementary aids to researchers
and clinicians for screening, evaluating, and monitoring FMS patients.
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OBJECTIVES:Telemedicine is considered a potentially efficient and effectiveway to
provide physical exercise therapy. To foster uptake of telemedicine exercise ser-
vices and to improve treatment compliance, it is important that services address
patients’ needs and preferences. Therefore, this study examines patients’ prefer-
ences of different telemedicine exercise services using a conjoint experiment.
METHODS: Implemented as part of a larger survey, preferences were estimated
using a choice-based conjoint experiment, spanning six relevant attributes of tele-
medicine exercise services. Attributes were indentified by means of qualitative
interviews and an expert focus group and included a) exercise mode and location;
b) presence of monitoring and feedback technology; c) counseling type; d) counsel-
ing frequency; e) flexibility of exercise hours; and f) willingness to accept as ex-
pressed in terms of a reduction in healthcare insurance premiums. Each patient
was presented with 15 choice tasks, consisting of two exercise service profiles and
an opt-out scenario. A bivariate probit regression analysis was used to estimate
preferences. RESULTS: Hundred and three patients were included in the analysis
after checking for patients’ understanding of the questionnaire using a dominant
option validity check. Themost important attribute levels were individual exercise
at gym, the use of monitoring and feedback technology, 100% face-to-face coun-
seling, counseling every session, flexible exercise hours and 45% health care insur-
ance reduction. Assistive telemedicine was preferred the most, over conventional
treatment and home-based telemedicine. Home-based telemedicinewas preferred
the least and ahealth care insurance reduction of 181 eurowould increase its utility
to the level of conventional treatment. CONCLUSIONS: Results show that patient-
centered telemedicine exercise services should integrate feedback andmonitoring
technology during treatment and emphasize the importance of supplementary
face-to-face counseling sessions. Offering health care insurance reduction could be
a way to further foster uptake of these future telemedicine services.
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OBJECTIVES: Rheumatoid arthritis (RA) is an incapacitating disease with prevalence
estimates ranging from 0.5% to 1% in Brazil, which demands early diagnose and ade-
quate treatment to slow down it’s progression. This study is aimed to assess co-mor-
bidity, quality of life (QoL), work/productivity loss, andmedical resource utilization in
patients diagnosed with RA in Brazil.METHODS: A total of 12,000 individuals’ (age
18) self-reported data were collected from 2011 National Health and Wellness
Survey (NHWS) in Brazil, a cross-sectional representative sample of the adult pop-
ulation. QOL was measured by the physical component score (PCS) and mental
component score (MCS) of the Short Form-12 (SF-12). Loss ofwork/productivitywas
measured by the validatedWork Productivity andActivity Impairment instrument.
Medical resource utilization was measured by health care provider utilization,
emergency room visits and hospitalization in the past 6 months. RESULTS: Of the
12,000 respondents, 65 (0.5%) had been diagnosed with RA, fromwhich 58.0% were
female. 45% of RA diagnosed group reported RA related problems once a month or
less, 27% say their problems occur daily, and 28% experience problems more often
than once per month, but not daily. On average, RA patients have been diagnosed
for 14 years. RA diagnosed group was more likely to suffer from the co-morbidities
of pain (59% vs.23%) and fibromyalgia (11%v s.1%), was more likely to visit an
emergency room in the past 6 months (41% vs.21%), presented lower mean PCS
scores (40% vs. 50%) and had higher percentages of absenteeism (9.2% vs.6.5%),
presenteeism (43.3% vs 14.5%)., work productivity loss (47%vs.18.5%) and activity
impairment (46.9% vs.20.3%) when compared to the group not diagnosed with RA.
All mentioned differences were statistically significant (p0.05). CONCLUSIONS:
Based on results from the Brazil NHWS, patients diagnosed with RA suffer from
impairment in QOL, work/productivity loss and more co-morbidities. Findings in-
dicate there is still an unmet medical need in RA patients in Brazil.
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OBJECTIVES: Poor nutrition, low dietary calcium intake, vitamin D deficiency, in-
sufficient exercise, smoking and alcohol usage aremodifiable risk factors that directly
affect bones and are associated with osteoporosis. In Brazil, there are no solid esti-
mates of the magnitude of the condition, due to being a country with a very hetero-
geneous racial, cultural and economic background. This study is aimed to assess co-
morbidity, quality of life (QOL), work/productivity loss, and medical resource
utilization in women with osteoporosis in Brazil. METHODS: A total of 12,000 indi-
viduals’ (age 18) self-reported data were collected from 2011 National Health and
Wellness Survey (NHWS) in Brazil. QOL was measured by the physical component
score (PCS) andmental component score (MCS) of the Short Form-12 (SF-12). Loss of
work/productivity was measured by the validated Work Productivity and Activity
Impairment instrument. Medical resource utilizationwasmeasured by health care
provider, emergency room visits and hospitalization in the past six months.
RESULTS: Of the 6017 female respondents, 179 (3.0%) were diagnosed with osteopo-
rosis (withorwithoutosteopenia) and156 (1.8%)werediagnosedwithosteopeniaonly.
Average age forwomendiagnosedwith osteoporosis/osteopeniawas 59.6 years. Diag-
nosed osteoporosis/osteopenia group reported more co-morbidities (headache 44%,
pain 36%, insomnia 26%, migraine 23%, depression 22%, arthritis 22%), lower mean
scores of PCS (42.6 vs.47.33) and MCS (45.7 vs. 50.3), more patients visited healthcare
providers (93%vs. 79%), and a higher percentage were using any cost-saving strategy
(55%vs. 37%)over thepast 6months compared tonon-osteoporosis/osteopeniagroup.
Furthermore, osteoporosis/osteopenia group reported 35.8% impairment in daily ac-
tivity compared to 23.0% innon-osteoporosis/osteopenia group.All comparisonswere
statistically significant at p 0.05. CONCLUSIONS: Based on results from the Brazil
NHWS, women diagnosed with osteoporosis/osteopenia suffer from impairment in
QOL,work/productivity loss, greater usage of health care resources andmore co-mor-
bidities. Findings indicate there is still an unmet medical need in osteoporosis/os-
teopenia patients in Brazil.
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OBJECTIVES: To measure the quality of life (QOL) in ankylosing sporidylitis (AS)
patients treated with Infliximab in China. METHODS: Patients’ self-reported data
were collected from a longitudinal survey which was conducted between June 10,
2009 and October 18, 2011 in AS patients at 40 urban hospitals in 23 cities in China.
QOL wasmeasured by Short Form-12 (SF-12) and each follow-up visit up to 8 visits.
RESULTS: Of the 609 survey respondents, 13.0% were treated with Infliximab (ex-
perienced-Infliximab group (EIG)) at baseline and follow ups, while 87.0% were not
treated with Infliximab at baseline but went on Infliximab treatment at the follow
ups (new-Infliximab group (NIG)). These two groups had no significant difference
with respect to age, gender and duration. Comparing with those in the NIG at
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